Eisai Co. Ltd.

History

Year	Detail
1941	Nihon Eisai Co. Ltd. is established in Saitama, eastern Japan.
1944	Sakuragaoka Laboratory Co. Ltd. and Nihon Eisai Co. Ltd. merge under the name Nihon Eisai Co. Ltd.
1950	Launched cardiotonic Neophyllin in Japan.
1952	Nihon Eisai Co. Ltd. launches high-dosage vitamin B1 and B2 product Chocola BB Tablets in Japan.
1955	The company changes its name from Nihon Eisai Co. Ltd. to Eisai Co. Ltd.
1961	Eisai opens its Taipei Office.
1969	Youda Co. Ltd. is established as a pharmaceutical imports subsidiary in Taiwan.
1970	PT Eisai Indonesia is established.
1971	Toyoji opens the Naito Museum of Pharmaceutical Science and Industry.
1974	Eisai (Malaysia) Sdn. Bhd. and Hi-Eisai Pharmaceutical Inc. are established as pharmaceutical sales subsidiaries in Malaysia and the Philippines, respectively.
1977	Launched Naturally derived vitamin E product Juvelux.
1981	Eisai U.S.A. Inc. is established.
1982	The Tsukuba Research Laboratories open in Ibaraki, eastern Japan.
1989	Eisai Machinery GmbH is established in Germany.
1995	Eisai Inc. is established as a pharmaceutical sales subsidiary in New Jersey, the U.S.
1998	Aricept is launched in France.
2004	Eisai Europe Ltd. is established.
2008	Eisai acquires MGI Pharma Inc.
2018	Eisai agrees upon a strategic collaboration for Lenvima with Merck & Co. Inc. and Kenilworth.
2020	Unlimit Health Limited is established in Shanghai, China.
2022	Eisai Pharmaceuticals Africa (Pty) Ltd is established.
2023	LEQEMBI is launched in Japan.